In 1998, trastuzumab (Herceptin®) was approved by the FDA as the first targeted therapeutic drug for metastatic HER2+ BC, and the first humanized monoclonal antibody targeted against the HER2 protein [15]. This evidence concerns the gene ERBB2 and breast cancer.